Integrin Alpha V in Urine: A Novel Noninvasive Marker for Prostate Cancer Detection

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Apr 1

PMID 33791193

Citations 3

Authors

Marina Y Zemskova

Maria V Marinets

Andrey V Sivkov

Julia V Pavlova

Andrey N Shibaev

Konstantin S Sorokin

Affiliations

Soon will be listed here.

Abstract

Materials And Methods: Urinary ITGAV expression was determined by Western blot analysis and quantified by ELISA in urine from men with PCa (n = 47), benign prostate hyperplasia (n = 42) and age-matched controls (n = 22).

Results: The level of ITGAV protein was significantly lower in PCa urine samples as compared to those in the control group (p < 0.00001). The decrease of ITGAV in urine was highly predictive of PCa with 91.5% sensitivity, 91.4% specificity, 0.93 area under the ROC curve, and its specificity was better than that of serum PSA.

Conclusion: Urinary ITGAV provides a novel noninvasive biomarker with high specificity.

Citing Articles

A novel class of inhibitors that disrupts the stability of integrin heterodimers identified by CRISPR-tiling-instructed genetic screens.

Mattson N, Chan A, Miyashita K, Mukhaleva E, Chang W, Yang L Nat Struct Mol Biol. 2024; 31(3):465-475.

PMID: 38316881 PMC: 10948361. DOI: 10.1038/s41594-024-01211-y.

The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery.

Samarzija I Biomedicines. 2024; 12(1).

PMID: 38255186 PMC: 10813710. DOI: 10.3390/biomedicines12010079.

Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker.

Skara L, Vodopic T, Pezelj I, Abramovic I, Vrhovec B, Vrtaric A Biomol Biomed. 2022; 23(1):176-186.

PMID: 36036057 PMC: 9901895. DOI: 10.17305/bjbms.2022.7497.

References

Lee B, Mahmud I, Marchica J, Derezinski P, Qi F, Wang F . Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery. Sci Rep. 2020; 10(1):3716. PMC: 7048821. DOI: 10.1038/s41598-020-60616-z. View

Shtricker A, Shefi S, Ringel A, Gillon G . PSA levels of 4.0 - 10 ng/mL and negative digital rectal examination. Antibiotic therapy versus immediate prostate biopsy. Int Braz J Urol. 2009; 35(5):551-5. DOI: 10.1590/s1677-55382009000500006. View

Thompson I, Ankerst D, Chi C, Lucia M, Goodman P, Crowley J . Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005; 294(1):66-70. DOI: 10.1001/jama.294.1.66. View

Gerke V, Creutz C, Moss S . Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005; 6(6):449-61. DOI: 10.1038/nrm1661. View

Aregger F, Uehlinger D, Witowski J, Brunisholz R, Hunziker P, Frey F . Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury. Kidney Int. 2013; 85(4):909-19. DOI: 10.1038/ki.2013.363. View

Goel H, Li J, Kogan S, Languino L . Integrins in prostate cancer progression. Endocr Relat Cancer. 2008; 15(3):657-64. PMC: 2668544. DOI: 10.1677/ERC-08-0019. View

Li P, Yu X, Han W, Kong Y, Bao W, Zhang J . Ultrasensitive and Reversible Nanoplatform of Urinary Exosomes for Prostate Cancer Diagnosis. ACS Sens. 2019; 4(5):1433-1441. DOI: 10.1021/acssensors.9b00621. View

Bolduc S, Lacombe L, Naud A, Gregoire M, Fradet Y, Tremblay R . Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J. 2008; 1(4):377-81. PMC: 2422995. DOI: 10.5489/cuaj.444. View

Krishn S, Singh A, Bowler N, Duffy A, Friedman A, Fedele C . Prostate cancer sheds the αvβ3 integrin in vivo through exosomes. Matrix Biol. 2018; 77:41-57. PMC: 6541230. DOI: 10.1016/j.matbio.2018.08.004. View

10.

Schostak M, Schwall G, Poznanovic S, Groebe K, Muller M, Messinger D . Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol. 2008; 181(1):343-53. DOI: 10.1016/j.juro.2008.08.119. View

11.

Hamidi H, Pietila M, Ivaska J . The complexity of integrins in cancer and new scopes for therapeutic targeting. Br J Cancer. 2016; 115(9):1017-1023. PMC: 5117799. DOI: 10.1038/bjc.2016.312. View

12.

Deras I, Aubin S, Blase A, Day J, Koo S, Partin A . PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008; 179(4):1587-92. DOI: 10.1016/j.juro.2007.11.038. View

13.

McCabe N, De S, Vasanji A, Brainard J, Byzova T . Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene. 2007; 26(42):6238-43. PMC: 2753215. DOI: 10.1038/sj.onc.1210429. View

14.

Prager A, Peng C, Lita E, McNally D, Kaushal A, Sproull M . Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. Biomark Med. 2013; 7(6):831-41. PMC: 6639092. DOI: 10.2217/bmm.13.112. View

15.

Lin Y, Chen F, Shen L, Tang X, Du C, Sun Z . Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model. J Transl Med. 2018; 16(1):134. PMC: 5963164. DOI: 10.1186/s12967-018-1506-7. View

16.

Wu X, Gong S, Roy-Burman P, Lee P, Culig Z . Current mouse and cell models in prostate cancer research. Endocr Relat Cancer. 2013; 20(4):R155-70. PMC: 3855867. DOI: 10.1530/ERC-12-0285. View

17.

Thompson I, Ankerst D, Chi C, Goodman P, Tangen C, Lucia M . Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006; 98(8):529-34. DOI: 10.1093/jnci/djj131. View

18.

Lu H, Wang T, Li J, Fedele C, Liu Q, Zhang J . αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Res. 2016; 76(17):5163-74. PMC: 5012867. DOI: 10.1158/0008-5472.CAN-16-0543. View

19.

Pandha H, Sorensen K, Orntoft T, Langley S, Hoyer S, Borre M . Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int. 2012; 110(6 Pt B):E287-92. DOI: 10.1111/j.1464-410X.2012.11208.x. View

20.

Drake R, White K, Fuller T, Igwe E, Clements M, Nyalwidhe J . Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics. 2009; 72(6):907-17. PMC: 2720443. DOI: 10.1016/j.jprot.2009.01.007. View